Summary
Synopsys, Inc. (SNPS) reported a solid performance for the quarter ending April 30, 2020, with total revenue increasing by 3% year-over-year to $861.3 million. This growth was primarily driven by strong performance in its time-based products and the Software Integrity segment, indicating continued demand for its electronic design automation (EDA) and software security solutions. Despite the global economic uncertainties brought on by the COVID-19 pandemic, Synopsys demonstrated resilience. The company maintained healthy operating income, up 9% year-over-year, and healthy cash flow from operations. While some segments experienced minor disruptions, the company's diversified business model and its revenue recognition policy for software licenses over the arrangement period have helped to mitigate immediate impacts. Management expressed confidence in its ability to meet its liquidity needs and navigate the evolving economic landscape.
Financial Highlights
57 data points| Revenue | $861.33M |
| Cost of Revenue | $184.26M |
| Gross Profit | $677.06M |
| R&D Expenses | $302.57M |
| Operating Expenses | $551.17M |
| Operating Income | $125.89M |
| Interest Expense | $1.85M |
| Net Income | $109.92M |
| EPS (Basic) | $0.73 |
| EPS (Diluted) | $0.71 |
| Shares Outstanding (Basic) | 150.60M |
| Shares Outstanding (Diluted) | 154.38M |
Key Highlights
- 1Total revenue for the three months ended April 30, 2020, increased by 3% to $861.3 million compared to the prior year.
- 2Operating income grew by 9% year-over-year to $125.9 million.
- 3Time-based products revenue saw a 6% increase, highlighting consistent demand for core offerings.
- 4The Software Integrity segment revenue grew by 6% for the quarter, demonstrating expansion in the software security and quality market.
- 5Cash provided by operating activities for the six months ended April 30, 2020, significantly increased by $180.9 million to $389.7 million.
- 6The company maintained a strong balance sheet with cash and cash equivalents increasing by 18% to $856.4 million.
- 7Despite the COVID-19 pandemic, the company has not identified material impairments or adverse effects to date, though it acknowledges ongoing uncertainty.